68 related articles for article (PubMed ID: 26658237)
1. PPX and Concurrent Radiation for Newly Diagnosed Glioblastoma Without MGMT Methylation: A Randomized Phase II Study: BrUOG 244.
Elinzano H; Glantz M; Mrugala M; Kesari S; Piccioni DE; Kim L; Pan E; Yunus S; Coyle T; Timothy K; Evans D; Mantripragada K; Boxerman J; DiPetrillo T; Donahue JE; Hebda N; Mitchell KM; Rosati KL; Safran H
Am J Clin Oncol; 2018 Feb; 41(2):159-162. PubMed ID: 26658237
[TBL] [Abstract][Full Text] [Related]
2. Patients Affected by Unmethylated O(6)-Methylguanine-DNA Methyltransferase Glioblastoma Undergoing Radiochemotherapy May Benefit from Moderately Dose-Escalated Radiotherapy.
Tini P; Nardone V; Pastina P; Battaglia G; Miracco C; Sebaste L; Rubino G; Cerase A; Pirtoli L
Biomed Res Int; 2017; 2017():9461402. PubMed ID: 29159183
[TBL] [Abstract][Full Text] [Related]
3. Predictive value of diffusion MRI-based parametric response mapping for prognosis and treatment response in glioblastoma.
Rydelius A; Bengzon J; Engelholm S; Kinhult S; Englund E; Nilsson M; Lätt J; Lampinen B; Sundgren PC
Magn Reson Imaging; 2023 Dec; 104():88-96. PubMed ID: 37734574
[TBL] [Abstract][Full Text] [Related]
4. Integration of autologous dendritic cell-based immunotherapy in the standard of care treatment for patients with newly diagnosed glioblastoma: results of the HGG-2006 phase I/II trial.
Ardon H; Van Gool SW; Verschuere T; Maes W; Fieuws S; Sciot R; Wilms G; Demaerel P; Goffin J; Van Calenbergh F; Menten J; Clement P; Debiec-Rychter M; De Vleeschouwer S
Cancer Immunol Immunother; 2012 Nov; 61(11):2033-44. PubMed ID: 22527250
[TBL] [Abstract][Full Text] [Related]
5. Clinical trials of R-(-)-gossypol (AT-101) in newly diagnosed and recurrent glioblastoma: NABTT 0602 and NABTT 0702.
Fiveash JB; Ye X; Peerboom DM; Mikkelsen T; Chowdhary S; Rosenfeld M; Lesser GJ; Fisher J; Desideri S; Grossman S; Leopold L; Nabors LB
PLoS One; 2024; 19(1):e0291128. PubMed ID: 38285688
[TBL] [Abstract][Full Text] [Related]
6. Adjuvant re-irradiation vs. no early re-irradiation of resected recurrent glioblastoma: pooled comparative cohort analysis from two tertiary centers.
Straube C; Combs SE; Bernhardt D; Gempt J; Meyer B; Zimmer C; Schmidt-Graf F; Vajkoczy P; Grün A; Ehret F; Zips D; Kaul D
J Neurooncol; 2024 May; 168(1):49-56. PubMed ID: 38520571
[TBL] [Abstract][Full Text] [Related]
7. Bevacizumab and fotemustine for recurrent glioblastoma: a phase II study of AINO (Italian Association of Neuro-Oncology).
Soffietti R; Trevisan E; Bertero L; Cassoni P; Morra I; Fabrini MG; Pasqualetti F; Lolli I; Castiglione A; Ciccone G; Rudà R
J Neurooncol; 2014 Feb; 116(3):533-41. PubMed ID: 24293233
[TBL] [Abstract][Full Text] [Related]
8. Comparative study of concurrent conventional chemoradiotherapy versus hypofractionated chemoradiotherapy in newly diagnosed glioblastoma multiforme postoperative patients.
Khatri NK; Kumar HS; Sharma N; Jakhar SL; Dhaka S
J Cancer Res Ther; 2023; 19(5):1126-1130. PubMed ID: 37787273
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of chlorpromazine as an adjuvant therapy for glioblastoma in patients with unmethylated
Pace A; Lombardi G; Villani V; Benincasa D; Abbruzzese C; Cestonaro I; Corrà M; Padovan M; Cerretti G; Caccese M; Silvani A; Gaviani P; Giannarelli D; Ciliberto G; Paggi MG
Front Oncol; 2023; 13():1320710. PubMed ID: 38162492
[TBL] [Abstract][Full Text] [Related]
10. Marizomib for patients with newly diagnosed glioblastoma: a randomized phase 3 trial.
Roth P; Gorlia T; Reijneveld JC; de Vos F; Idbaih A; Frenel JS; Le Rhun E; Sepulveda JM; Perry J; Masucci GL; Freres P; Hirte H; Seidel C; Walenkamp A; Lukacova S; Meijnders P; Blais A; Ducray F; Verschaeve V; Nicholas G; Balana C; Bota DA; Preusser M; Nuyens S; Dhermain F; van den Bent M; O'Callaghan CJ; Vanlancker M; Mason W; Weller M;
Neuro Oncol; 2024 Mar; ():. PubMed ID: 38502052
[TBL] [Abstract][Full Text] [Related]
11. The addition of Valproic acid to concurrent radiation therapy and temozolomide improves patient outcome: a Correlative analysis of RTOG 0525, SEER and a Phase II NCI trial.
Krauze AV; Megan M; Theresa CZ; Peter M; Shih JH; Tofilon PJ; Rowe L; Gilbert M; Camphausen K
Cancer Stud Ther; 2020 Mar; 5(1):. PubMed ID: 34621499
[TBL] [Abstract][Full Text] [Related]
12. Autologous Heat Shock Protein Peptide Vaccination for Newly Diagnosed Glioblastoma: Impact of Peripheral PD-L1 Expression on Response to Therapy.
Bloch O; Lim M; Sughrue ME; Komotar RJ; Abrahams JM; O'Rourke DM; D'Ambrosio A; Bruce JN; Parsa AT
Clin Cancer Res; 2017 Jul; 23(14):3575-3584. PubMed ID: 28193626
[No Abstract] [Full Text] [Related]
13. Diffusion MR Characteristics Following Concurrent Radiochemotherapy Predicts Progression-Free and Overall Survival in Newly Diagnosed Glioblastoma.
Chang W; Pope WB; Harris RJ; Hardy AJ; Leu K; Mody RR; Nghiemphu PL; Lai A; Cloughesy TF; Ellingson BM
Tomography; 2015 Sep; 1(1):37-43. PubMed ID: 26740971
[TBL] [Abstract][Full Text] [Related]
14. Simultaneous boost radiotherapy versus conventional dose radiotherapy for patients with newly diagnosed glioblastoma: a multi-institutional analysis.
Takano S; Tomita N; Kuno M; Niwa M; Torii A; Takaoka T; Kita N; Okazaki D; Yamamoto S; Kawai T; Sugie C; Ogawa Y; Matsumoto K; Uchiyama K; Otsuka S; Matsui T; Miyakawa A; Mizuno T; Iida M; Tanikawa M; Mase M; Hiwatashi A
Sci Rep; 2024 Apr; 14(1):9283. PubMed ID: 38654028
[TBL] [Abstract][Full Text] [Related]
15. Biological and clinical characterization of paclitaxel poliglumex (PPX, CT-2103), a macromolecular polymer-drug conjugate.
Chipman SD; Oldham FB; Pezzoni G; Singer JW
Int J Nanomedicine; 2006; 1(4):375-83. PubMed ID: 17722272
[TBL] [Abstract][Full Text] [Related]
16. Temozolomide chronotherapy in patients with glioblastoma: a retrospective single-institute study.
Damato AR; Luo J; Katumba RGN; Talcott GR; Rubin JB; Herzog ED; Campian JL
Neurooncol Adv; 2021; 3(1):vdab041. PubMed ID: 33959716
[TBL] [Abstract][Full Text] [Related]
17. Inaugural Results of the Individualized Screening Trial of Innovative Glioblastoma Therapy: A Phase II Platform Trial for Newly Diagnosed Glioblastoma Using Bayesian Adaptive Randomization.
Rahman R; Trippa L; Lee EQ; Arrillaga-Romany I; Fell G; Touat M; McCluskey C; Wiley J; Gaffey S; Drappatz J; Welch MR; Galanis E; Ahluwalia MS; Colman H; Nabors LB; Hepel J; Elinzano H; Schiff D; Chukwueke UN; Beroukhim R; Nayak L; McFaline-Figueroa JR; Batchelor TT; Rinne ML; Kaley TJ; Lu-Emerson C; Mellinghoff IK; Bi WL; Arnaout O; Peruzzi PP; Haas-Kogan D; Tanguturi S; Cagney D; Aizer A; Doherty L; Lavallee M; Fisher-Longden B; Dowling S; Geduldig J; Watkinson F; Pisano W; Malinowski S; Ramkissoon S; Santagata S; Meredith DM; Chiocca EA; Reardon DA; Alexander BM; Ligon KL; Wen PY
J Clin Oncol; 2023 Dec; 41(36):5524-5535. PubMed ID: 37722087
[TBL] [Abstract][Full Text] [Related]
18. Intracerebral administration of CpG oligonucleotide for patients with recurrent glioblastoma: a phase II study.
Carpentier A; Metellus P; Ursu R; Zohar S; Lafitte F; Barrié M; Meng Y; Richard M; Parizot C; Laigle-Donadey F; Gorochov G; Psimaras D; Sanson M; Tibi A; Chinot O; Carpentier AF
Neuro Oncol; 2010 Apr; 12(4):401-8. PubMed ID: 20308317
[TBL] [Abstract][Full Text] [Related]
19. L-RNA aptamer-based CXCL12 inhibition combined with radiotherapy in newly-diagnosed glioblastoma: dose escalation of the phase I/II GLORIA trial.
Giordano FA; Layer JP; Leonardelli S; Friker LL; Turiello R; Corvino D; Zeyen T; Schaub C; Müller W; Sperk E; Schmeel LC; Sahm K; Oster C; Kebir S; Hambsch P; Pietsch T; Bisdas S; Platten M; Glas M; Seidel C; Herrlinger U; Hölzel M
Nat Commun; 2024 May; 15(1):4210. PubMed ID: 38806504
[TBL] [Abstract][Full Text] [Related]
20. Phase I study targeting newly diagnosed grade 4 astrocytoma with bispecific antibody armed T cells (EGFR BATs) in combination with radiation and temozolomide.
Fadul CE; Thakur A; Kim J; Kassay-McAllister J; Schalk D; Lopes MB; Donahue J; Purow B; Dillon P; Le T; Schiff D; Liu Q; Lum LG
J Neurooncol; 2024 Jan; 166(2):321-330. PubMed ID: 38263486
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
